Linhui Wang

Linhui Wang

Auto-generated profile, based on publicly available information

Linhui Wang

Department of Urology The Second Hospital of Tianjin Medical University Tianjin China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2021 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
LWLinhui Wang
Linhui Wang
YWYutao Wang
Yutao Wang
JWJianfeng Wang
Jianfeng Wang
LLLuanfeng Li
Luanfeng Li
YFYang Fu
Yang Fu
Background. Bladder cancer is the tenth most common cancer worldwide. Valuable biomarkers in the field of diagnostic bladder cancer are urgently required. Method. Here, the gene expression matrix and clinical data were obtained from The Cancer Genome Atlas (TCGA), GSE13507, GSE32894, and Mariathasan et al. Five prognostic genes were identified by the univariate, robust, and multivariate Coxs regression and were used to develop a prognosis-related model. The KaplanMeier survival curves and receiver operating characteristics were used to evaluate the models effectiveness. The potential biological functions of the selected genes were analyzed using CIBERSORT and ESTIMATE algorithms. Cancer Therapeutics Response Portal (CTRP) and PRISM datasets were used to identify drugs with high sensitivity. Subsequently, using the bladder cancer (BLCA) cell lines, the role of TNFRSF14 was determined by Western blotting, cell proliferation assay, and 5-ethynyl-20-deoxyuridine assay. Results. GSDMB, CLEC2D, APOL2, TNFRSF14, and GBP2 were selected as prognostic genes in bladder cancer patients. The models irreplaceable reliability was validated by the training and validation cohorts. CD8+ T cells were highly infiltrated in the high-TNFRSF14-expression group, and M2 macrophages were the opposite. Higher expression of TNFRSF14 was associated with higher expression levels of LCK, interferon, MHC-I, and MHC-II, while risk score was the opposite. Many compounds with higher sensitivity for treating bladder cancer patients in the low-TNFRSF14-expression group were identified, with obatoclax being a potential drug most likely to treat patients in the low-TNFRSF14-expression group. Finally, the proliferation of BLCA cell lines was increased in the TNFRSF14-reduced group, and the differential expression was identified. TNFRSF14 plays a role in bladder cancer progression through the Wnt/β-catenin-dependent pathway. TNFRSF14 is a potential protective biomarker involved in cell proliferation in BLCA. Conclusion. We conducted a study to establish a 5-gene score model, providing reliable prediction for the outcome of bladder cancer patients and therapeutic drugs to individualize therapy. Our findings provide a signature that might help determine the optimal treatment for individual patients with bladder cancer.

27 September 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
LWLinhui Wang
Linhui Wang
XLXiaomeng Liu
Xiaomeng Liu
TZTao Zhu
Tao Zhu
ZSZirun Su
Zirun Su
RLRuiping Liu
Ruiping Liu
HHHailong Hu
Hailong Hu
Cisplatin (CDDP) chemosensitivity and severe toxicity severely limit its clinical application in muscle‐invasive bladder cancer (MIBC) and non‐muscle‐invasive bladder cancer (NMIBC). To address these unmet clinical needs, we synthesized a series of melatonin‐conjugated platinum(IV) prodrugs functionalized with isocyanate chains (compounds 5 ‒ 12 ), and identified MP‐12C (compound 11 ) as the lead candidate with optimal potency and safety. In vitro assays showed that MP‐12C exhibited far stronger antiproliferative activity than CDDP and mitomycin C in parental and CDDP‐resistant bladder cancer cells. Multiple in vivo models, including subcutaneous xenograft, orthotopic, and chemically induced spontaneous bladder cancer models, were adopted. Both intravenous injection and intravesical instillation of MP‐12C achieved robust tumor suppression while reducing toxicity compared to conventional chemotherapeutics. Mechanistically, MP‐12C downregulated the TCF4/COL6A3 axis to suppress collagen VI secretion by bladder cancer cells, thereby remodeling the extracellular matrix (ECM) and enhancing the sensitivity of bladder cancer cells to CDDP. MP‐12C triggered immunogenic cell death and persistently activated the cGAS‐STING pathway, promoting dendritic cell maturation and CD8 + T cell infiltration to remodel the antitumor immune microenvironment. Collectively, MP‐12C integrates ECM modulation and immune activation to exert superior anti‐bladder cancer efficacy with favorable safety, thus providing a promising platinum(IV) prodrug strategy for NMIBC and MIBC.